"us bioc secure act I think is a huge opportunity for it's mainly addresses biotechnology because it doesn't want genome mapping data to be to be late because that can be used for you know treating humans better like you were talking about earlier that these Pharma companies will not tell you the Cure they'll just give you the bandage right so they'll want to keep making more and more business but a lot of work is happening in this genome sequencing thing in order to sort of give you the medicine that you actually need yes right without having you know so that you can be cured better or you can really be fixed for life so any Indian companies who are doing that you know one opportunity is in contract manufacturing because Indians are not innovators that's true yeah so and drugs so a lot of uh I think drugs worth if my data is right about $5 billion are going off patent next two years and then you will have the generic versions available that can be out so that will help there's a lot of work happening on few antibiotics we we haven't had any new antibiotic for last 10 15 years really India not made any antibiotic there's world over there's been not many antibiotics so you need more antibiotics and there couple of antibiotics which been researched then fertility become a big issue uh unfortunately the conceive you know the women are not able to conceive uh because you know people start their family late biological changes so a lot of companies coming in fertility centers IVF they are so wom Healthcare would be another very very big Focus right uh area so you have to be in Subs the other thing in India is India is a branded generic market so you had the doctor wres take Doo uh take crin take D us you buy the salt in US you'll say paracetamol H so us it's India it's like fmcg it's sold like a doctor prescribed right so that is why Indian Pharma companies have a higher margin that is why a Sia a Mankind Pharma has done better than a son which is into generics so go for Branded guys more uh in Pharma go for contract manufacturers more and look at hospitals I think I think hospitals will be a in my view uh we are we are I think in terms of number of ICU beds per patient we are wul short okay we need more what is the short huge shortage I think we don't I think it's one in some 10,000 or 15,000 when Co happened we all of us remember what happened there were no beds so I think hospital capex will go up as as as as see it's like chicken egg more insurance coverage more affordability more beds you know it's all it's all linked yeah I think all of that will happen"
By Finance With Sharan | January 6, 2025 | Correct
From video
How to Identify Multi-bagger Stocks in 2025 | Ep. 48 01:09:01 - 01:11:38
Interpreted Prediction
Biotechnology, particularly contract manufacturing for generics (as $5 billion worth of drugs go off-patent in the next two years), and women's healthcare (fertility centers, IVF) will present significant opportunities. Hospital capex will also increase due to a severe shortage of ICU beds and rising insurance coverage/affordability.
AI Evaluation Notes
Evaluated on 2026-04-21
The prediction correctly identified structural growth trends in Indian healthcare, including the Biosecure Act's benefit to CDMOs, the expansion of branded generics, and increased hospital capex driven by capacity shortages. These sectors have generally outperformed or met the growth expectations outlined in the 2025 forecast.

Prediction Details

Topic

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.